Janine Forche, PA
Medical · Lambertville, MINPI 1023145018
Payments from drug & device makers
Across 404 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$952
- AbbVie$786
- Novo Nordisk$750
- AstraZeneca$672
- Lilly USA, LLC$529
- GSK$296
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,739100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 40 | $952 |
| AbbVie | 55 | $786 |
| Novo Nordisk | 55 | $750 |
| AstraZeneca | 29 | $672 |
| Lilly USA, LLC | 38 | $529 |
| GSK | 18 | $296 |
| Exact Sciences | 17 | $247 |
| Pfizer | 15 | $226 |
| Otsuka America Pharmaceutical, Inc. | 14 | $217 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $217 |
| Boehringer Ingelheim | 11 | $195 |
| Axsome Therapeutics, Inc. | 8 | $182 |
| Amgen | 11 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $154 |
| Jazz Pharmaceuticals Inc. | 8 | $134 |
| Merck | 7 | $115 |
| Biohaven Pharmaceuticals, Inc. | 8 | $115 |
| Johnson & Johnson | 6 | $95 |
| Neurocrine Biosciences, Inc. | 6 | $94 |
| Bayer | 5 | $90 |
| Amarin Pharma, Inc. | 6 | $87 |
| Dexcom, Inc. | 4 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Novartis | 2 | $36 |
| Upsher-smith Laboratories LLC | 2 | $34 |
| Phadia US Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Abbott | 1 | $13 |
| Kaleo, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $10 |
How this compares
$6,751 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 67 | $72,582 |
| EliquisApixaban | 60 | $50,644 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $43,690 |
| OzempicSemaglutide | 33 | $32,350 |
| JanuviaSitagliptin Phosphate | 21 | $30,248 |
| RybelsusSemaglutide | 15 | $27,083 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $26,959 |
| MounjaroTirzepatide | 16 | $18,782 |
| XareltoRivaroxaban | 17 | $15,120 |
| TrulicityDulaglutide | 15 | $14,370 |
| FarxigaDapagliflozin Propanediol | 15 | $14,183 |
| MyrbetriqMirabegron | 17 | $12,947 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $8,888 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,066 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $7,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $296 | $79,537112 claims |
| Boehringer IngelheimJardiance | $195 | $72,58267 claims |
| Novo NordiskOzempic, Rybelsus | $750 | $59,43348 claims |
| PfizerEliquis | $226 | $50,64460 claims |
| Lilly USA, LLCMounjaro, Trulicity | $529 | $33,15231 claims |
| MerckJanuvia | $115 | $30,24821 claims |
| AstraZenecaFarxiga, Symbicort | $672 | $20,77237 claims |
| Johnson & JohnsonXarelto | $95 | $15,12017 claims |
| AbbVieSynthroid | $786 | $1,50842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Lambertville
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.